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Frequently asked questions on opioid agonist treatment for 
pharmaceutical opioid dependence: An evidence summary 
This evidence summary comes from a program of work that aimed to build the evidence 
base for the treatment of pharmaceutical opioid dependence, or dependence on opioid pain 
medications such as oxycodone, morphine and codeine. Many of the original trials 
examining methadone and buprenorphine (+/- naloxone) were conducted in people 
dependent on heroin. In recent years new studies and revised analysis from older studies 
have aimed to provide information on the use of methadone and buprenorphine (+ naloxone) 
for those dependent on pharmaceutical opioids such as codeine, morphine and oxycodone. 
Below is a summary of key findings in a ‘frequently asked questions’ format. If you have 
other queries relating this body of research please get in touch at 
suzanne.nielsen@unsw.edu.au   
 
Q. Can methadone and buprenorphine be used to treatment dependence on 
pharmaceutical opioids such as codeine or oxycodone? 
A. Yes, there is a growing body of smaller studies (1, 2), in addition to a recent Cochrane 
review (3) that demonstrate that methadone and buprenorphine (+/- naloxone) can be used 
and are effective in the treatment of pharmaceutical opioid dependence. These medications 
are generally indicated for the treatment of ‘opioid dependence’, with no restriction on the 
type of opioid.  
 
Q. Is methadone or buprenorphine more effective in this population? 
A. A Cochrane review compared outcomes for methadone and buprenorphine for people 
dependent on pharmaceutical opioids. This review found no difference in treatment retention 
or opioid use between methadone and buprenorphine (3). This suggests that other factors 
such as patient preferences, stigma issues, logistics of treatment (e.g. access to take-away 
doses) and potential drug interactions may determine which treatment is most appropriate 
for an individual patient (4). It should be noted that in general, more research has been 
conducted with buprenorphine in pharmaceutical opioid dependent populations, which is 
reflected by more discussion of buprenorphine below, simply because there is more 
research to discuss. 
 
Q. How long are people who are dependent on pharmaceutical opioid agonists likely 
to require treatment? 
A. Studies of shorter periods of treatment with buprenorphine (2- and 12-weeks of 
buprenorphine) found almost all people (more than 90%) relapse to opioid use after ceasing 
buprenorphine treatment (5).  Meta-analyses of three studies that compared shorter-term 
treatments to maintenance pharmacotherapy also found better outcomes in treatment 
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retention and opioid use with longer-term treatments (3-6 months) (3). This suggests that 
longer treatment (> 3 months) is likely to be required for most people.  This is consistent with 
the earlier research on treatment of opioid dependence that finds that detoxification alone is 
rarely effective and treatments of at least 12 months are associated with lower rates of 
relapse (6, 7). 
 
Q. Do treatment outcomes with opioid agonist treatment differ between 
pharmaceutical opioid dependent people and heroin dependent people? 
A. Studies that have compared these two opioid dependent populations that people 
dependent on pharmaceutical opioids tend to have more favourable outcomes in terms of 
retention (i.e. more people stay in treatment) and reduced opioid use (8, 9).  These studies 
have generally compared outcomes in buprenorphine-naloxone treatment between those 
that were using a pharmaceutical opioid at treatment entry with those using heroin at 
treatment entry. Studies of prescription opioid dependent people have also found that any 
history of heroin dependence (even using once in a lifetime) was associated with poorer 
treatment outcomes, suggesting those who report a history of heroin use may be considered 
for additional support or more intensive treatment (5, 9).  
 
Q. What evidence is there regarding psychological treatments combined with opioid 
agonist treatments for pharmaceutical opioid dependent people? 
A. One larger study compared additional counseling to standard medical management, and 
found that the additional counseling did not improve outcomes over standard care (9). It was 
noted in this study that the standard care platform was of a greater intensity (one or twice 
weekly visits with the doctor) than usually seen with opioid agonist treatment. A secondary 
analyses compared a range of psychological adjuncts with buprenorphine+naloxone and 
found a trend towards better outcomes with those that received CBT, contingency 
management or a combination of both (9). It should be noted that while not many studies 
have examined psychological treatments with opioid agonist treatments for those dependent 
in pharmaceutical opioids, there is a well-established evidence base demonstrating the for 
those with pain or depression, multimodal treatments including cognitive behavioral therapy 
and other psychological treatments identified to be important in improving treatment 
outcomes. 
 
Q. What sorts of doses of methadone or buprenorphine are needed to treat 
pharmaceutical opioid dependence? 
A. The studies we have examined showed that doses of methadone and buprenorphine 
appear broadly comparable to doses used to treat heroin dependence (1, 2). Interestingly, in 
a retrospective case series, initial dose of oxycodone or morphine did not seem to be related 
to dose requirements with methadone or buprenorphine (2). Studies in people dependent on 
codeine have found that doses of buprenorphine are much higher than might be expected 
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based on the amount of codeine people were using at treatment entry, though there was a 
lot of variation between people highlighting that while larger doses are sometimes required, 
individual titration is important to prevent sedation (1). Larger studies that have compared 
buprenorphine doses for those dependent on heroin and those dependent on 
pharmaceutical opioids and found dose requirements did not differ (9), nor did doses 
requirements differ between different prescription opioids (10). What remains less clear 
however are the range of effective doses to treat pain and improve pain outcomes. 
Controlled studies examining the relationship between pain severity or pain interference and 
different methadone or buprenorphine doses have not been conducted to date.   
 
Q. Do induction outcomes onto buprenorphine vary for different opioids? 
A. We compared rates of precipitated withdrawal for prescription opioid dependent people 
versus heroin dependent people and found they were pretty similar (11). We did find, on 
average, that those with lower scores for opioid withdrawal doses at induction were more 
likely to experience precipitated withdrawal (10), highlighting the importance of patients 
showing objective (physical) signs of opioid withdrawal before the first opioid dose. No 
difference was found between opioid types for induction outcomes. 
 
Q. What about where patient have chronic pain and opioid dependence? 
A. Research examining the effect of pain on treatment outcomes appears mixed. Some find 
that pain is associated with greater opioid use and others find that those with pain may do 
better in treatment (5, 12). Importantly, those with chronic pain requiring opioids have been 
excluded from many higher quality studies (e.g. randomized controlled trials) (5, 12), 
meaning that we really need more research to inform this area. 
 
Lower quality retrospective reports suggest that for those with chronic pain and opioid 
dependence, pain may improve after being stabilized on buprenorphine, compared to when 
patients are on high doses of prescribed opioids such as oxycodone (13, 14).  
 
One small randomized controlled trial with 54 people compared buprenorphine and 
methadone for those with chronic pain and opioid dependence (15). This study found pain 
improved in both groups, and did not differ between methadone and buprenorphine treated 
patients.  
 
There does not seem to be any evidence suggesting that patients with chronic pain cannot 
be managed well with methadone or buprenorphine (+/- naloxone), however further studies 
may provide more information on treatment outcomes. 
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Q. How do I know if opioid agonist treatment is appropriate for my patient? 
A. Not all patients’ dependent on pharmaceutical opioids may want, or be appropriate for 
opioid agonist treatment. A detailed assessment of the patient’s history, treatment 
preferences, other treatment options, and potential appropriateness for opioid agonist 
treatment is required. A summary of the role of opioid agonist treatment is provided here:  
https://www.nps.org.au/australian-prescriber/articles/opioid-treatment-of-opioid-addiction 
 
Where do I find out more information about prescribing methadone and 
buprenorphine (+naloxone) in Australia? 
There are national guidelines for the use of medication assisted treatment for opioid 
dependence (4).  
http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/Publishing.nsf/content/ng-mat-
op-dep 
Each state or territory has different requirements. Your department of health is a good place 
to start. Some links are provided below: 
 
Victoria: 
https://www2.health.vic.gov.au/public-health/drugs-and-poisons/pharmacotherapy 
South Australia 
http://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/clinical+r
esources/clinical+programs/drug+and+alcohol+programs/gp+program+medication+assisted
+treatment+for+opioid+dependence 
Western Australia 
http://healthywa.wa.gov.au/Articles/N_R/Opioid-pharmacotherapy-in-the-community 
Northern Territory 
https://health.nt.gov.au/professionals/environmental-health/medical-practitioners-schedule-8-
medicines 
Queensland 
https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/medicines/drugs-of-
dependence/qld-opioid-treatment 
New South Wales 
http://www.health.nsw.gov.au/pharmaceutical/doctors/Pages/otp-medical-practitioners.aspx 
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Australian Capital Territory 
https://www.health.act.gov.au/sites/default/files/Optioid%20maintenance%20treament%20gu
idelines.pdf 
 
Tasmania 
http://www.dhhs.tas.gov.au/mentalhealth/alcohol_and_drug/services/opioid_pharmacotherap
y 
http://www.dhhs.tas.gov.au/mentalhealth/alcohol_and_drug/publications/statewide_strategy_
and_plans/tasmanian_opioid_pharmacotherapy_policy_and_clinical_practice_standards 
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